Reviva Pharmaceuticals Holdings Inc (NAS:RVPH)

$ 2.8058 0.0358 (1.29%) Market Cap: 92.63 Mil Enterprise Value: 88.66 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

Reviva Pharmaceuticals Holdings, Inc. Phase 3 RECOVER Topline Results Call Transcript
Oct 30, 2023
Reviva Pharmaceuticals Holdings, Inc. at Canaccord Genuity Growth Conference Transcript
Aug 10, 2023
Reviva Pharmaceuticals Holdings, Inc. at Lytham Partners Spring Investor Conference (Virtual) Panel Transcript
May 18, 2023
Reviva Pharmaceuticals Holdings, Inc. at Lytham Partners Spring Investor Conference (Virtual) Transcript
May 18, 2023
Reviva Pharmaceuticals Holdings, Inc. to Host Key Opinion Leader Webinar Transcript
May 02, 2023
Reviva Pharmaceuticals Holdings, Inc. at ROTH Conference Transcript
Mar 13, 2023
Reviva Pharmaceuticals Holdings, Inc. at Lytham Partners Fall Investor Conference (Virtual) Transcript
Sep 28, 2022
Reviva Pharmaceuticals Holdings, Inc. at OTC Markets Life Sciences Virtual Investor Forum Transcript
Jun 23, 2022
Reviva Pharmaceuticals Holdings, Inc. to Host Key Opinion Leader Webinar for Schizophrenia and Other Neuropsychiatric Disorders Call Transcript
May 03, 2022
Reviva Pharmaceuticals Holdings, Inc. at Benzinga Healthcare Small Cap Conference (Virtual) Transcript
Sep 29, 2021

Reviva Pharmaceuticals Holdings, Inc. Phase 3 RECOVER Topline Results Call Transcript

Oct 30, 2023 / 12:30PM GMT

Release Date Price: $5.49 (+46.40%)

Transcript

Operator

Ladies and gentlemen, good morning. Welcome to Reviva Pharmaceuticals brilaroxazine program update conference call. (Operator Instructions)

As a reminder, this webcast is being recorded today, October 30, 2023. I will now turn the call over to Reviva's CEO, Lax Bhat. Please go ahead.

Lax Bhat

Reviva Pharmaceuticals Holdings, Inc. - CEO

Thank you. Good morning, and welcome everyone to the Reviva's brilaroxazine program update conference call. Earlier this morning, the Reviva issued a press release announcing positive topline results for the Phase 3 RECOVER study evaluating the efficacy, safety, and tolerability of brilaroxazine for adults with schizophrenia. A copy of this press release is available on the company's website through our SEC filings. Following our prepared remarks, we will hold a question-and-answer session with key opinion leader, Dr. Larry Ereshefsky, Chief Scientific Officer of Follow the Molecule, will join as well.

Please note that on today's call, we will be making forward-looking statements, which are based on current

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.